An adsorbent monolith device to augment the removal of uraemic toxins during haemodialysis
Autor: | Owen Boyd, Andrew Davenport, Susan Sandeman, Gary Phillips, Sergey V. Mikhalovsky, Carol Howell, Yishan Zheng, Kolitha Basnayake, Guy Standen, Robert Pletzenauer, Stephen G Holt |
---|---|
Jazyk: | angličtina |
Předmět: |
Biomedical Engineering
Biophysics Pilot Projects Bioengineering Absorption (skin) Sulfuric Acid Esters Article Absorption Biomaterials Cresols Adsorption Renal Dialysis Materials Testing medicine Humans Monolith Uremia geography Chromatography geography.geographical_feature_category Interleukin-6 Chemistry Albumin Membranes Artificial Equipment Design medicine.disease Indoxyl sulphate Equipment Failure Analysis Charcoal Chemical Engineering(all) Hemofiltration Indican Perfusion Kidney disease Activated carbon medicine.drug |
Zdroj: | Journal of Materials Science. Materials in Medicine |
ISSN: | 0957-4530 |
DOI: | 10.1007/s10856-014-5173-9 |
Popis: | Adsorbents designed with porosity which allows the removal of protein bound and high molecular weight uraemic toxins may improve the effectiveness of haemodialysis treatment of chronic kidney disease (CKD). A nanoporous activated carbon monolith prototype designed for direct blood contact was first assessed for its capacity to remove albumin bound marker toxins indoxyl sulphate (IS), p-cresyl sulphate (p-CS) and high molecular weight cytokine interleukin-6 in spiked healthy donor studies. Haemodialysis patient blood samples were then used to measure the presence of these markers in pre- and post-dialysis blood and their removal by adsorbent recirculation of post-dialysis blood samples. Nanopores (20–100 nm) were necessary for marker uraemic toxin removal during in vitro studies. Limited removal of IS and p-CS occurred during haemodialysis, whereas almost complete removal occurred following perfusion through the carbon monoliths suggesting a key role for such adsorbent therapies in CKD patient care. |
Databáze: | OpenAIRE |
Externí odkaz: |